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Abstract
Purpose Mutation frequencies of PROP1, POU1F1 and HESX1 in patients with combined pituitary hormone deficiencies 
(CPHD) vary substantially between populations. They are low in sporadic CPHD patients in Western Europe. However, 
most clinicians still routinely send DNA of their CPHD patients for genetic screening of these pituitary transcription fac-
tors. Before we can recommend against screening of PROP1, POU1F1 and HESX1 as part of routine work-up for Western-
European sporadic CPHD patients, it is crucial to rule out possible defects in regulatory regions of these genes, which could 
also disturb the complex process of pituitary organogenesis.
Methods The regulatory regions of PROP1, POU1F1 and HESX1 are not covered by Whole Exome Sequencing as they are 
largely located outside the coding regions. Therefore, we manually sequenced the regulatory regions, previously defined in 
the literature, of PROP1, POU1F1 and HESX1 among 88 Dutch patients with CPHD. We studied promoter SNPs in relation 
to phenotypic data.
Results We found six known SNPs in the PROP1 promoter. In the POU1F1 promoter, we found one new variant and two 
known SNPs. We did not find any variant in the HESX1 promoter.
Conclusion Although the new POU1F1 variant might explain the phenotype of one patient, the general conclusion of this 
study is that variants in regulatory regions of PROP1, POU1F1 and HESX1 are rare in patients with sporadic CPHD in the 
Netherlands. We recommend that genetic screening of these pituitary transcription factors should no longer be part of routine 
work-up for Western-European, and especially Dutch, sporadic CPHD patients.
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SNP  Single nucleotide polymorphism
SOD  Septo-optic dysplasia
T3/T4  Thyroid hormone
TRH  Thyrotropin-releasing hormone
TSH  Thyroid stimulating hormone
Introduction
Pituitary hormones are crucial for correct human growth 
and development. The anterior part of the pituitary (‘master 
gland’) is the central regulator of peripheral hormones. It 
contains somatotrope, lactotrope, gonadotrope, thyrotrope 
and corticotrope cells producing GH, PRL, LH/FSH, TSH 
and ACTH, respectively. Pituitary embryogenesis is a com-
plex process, which is orchestrated by a number of signaling 
molecules and transcription factors [1].
During pituitary organogenesis, regulation of the expres-
sion of pituitary transcription factors is crucial for normal 
pituitary development. Transcription factors bind to short 
DNA sequences usually located in the promoter region of 
a gene, to guide and activate DNA transcription. Hesx1 is 
one of the earliest transcription factors that appear in the 
pituitary gland. As studied in mice, Hesx1 and Prop1 exhibit 
temporally distinct but overlapping patterns of expression 
over the entire period of pituitary development. They het-
erodimerize on the same sequence element and Hesx1 sup-
presses Prop1 expression (and vice versa). Prop1 has to be 
present before Pou1f1 (formerly called Pit1) can be acti-
vated. Therefore the gene was referred to as Prophet of Pit1. 
However, premature expression of Prop1 can entirely block 
pituitary organogenesis [2].
Previous research has shown that bad timing or abnor-
mal amounts of transcription factors can disturb this com-
plex collaboration between transcription factors and lead to 
abnormal pituitary organogenesis and pituitary hormone 
deficiencies [3–6]. Since defects in the regulatory regions 
of a gene can alter expression of the gene, variations in regu-
latory regions of pituitary transcription factors are likely to 
also cause isolated or combined pituitary hormone deficien-
cies. This is supported by the work of Godi et al. [7], who 
found an association between two polymorphisms within 
and around a regulatory region in the intron 1 of PROP1 
(rs73346254A and rs148607624 delTAG), and combined 
pituitary hormone deficiencies (CPHD). Co-presence of the 
alternative alleles of both SNPs was associated with reduced 
transcriptional activity as shown by a decreased luciferase 
activity. An EMSA with oligonucleotide probes carrying the 
two alternative alleles demonstrated a strong difference in 
binding specificity of the two allelic sequences for a compo-
nent present in nuclear extracts from GH4C cells.
Although our knowledge of pituitary organogenesis and 
its genetics has increased tremendously in the past two 
decades, the exact genetic background of CPHD has not 
yet been clarified. Mutation frequencies reported in the lit-
erature vary substantially between populations. Figure 1a, 
b show the wide range of reported mutation frequencies 
from various countries, the highest prevalences being pre-
sent in Eastern Europe.
Therefore, the Dutch national HYPOPIT study was ini-
tiated, with the aim to determine the prevalence of genetic 
defects in the Dutch national cohort of patients with idi-
opathic pituitary hormone deficiencies.
Within the HYPOPIT study, we previously studied 
Dutch CPHD cases for mutations in PROP1, HESX1, 
POU1F1, LHX3, LHX4, OTX2, SHH and HHIP [22–24] 
and patients with Isolated GH Deficiency (IGHD) for 
GH1, GHRHR, HMGA2 and CDK6 [25–27]. In the cohort 
of CPHD patients, we found only one mutation, namely a 
missense mutation in POU1F1. In the IGHD cohort, we 
found GH1 mutations in 6% of the participating families, 
whereas we did not find any mutations in GHRHR or the 
regulatory regions of GH1.
This illustrates that only a small minority of the Dutch 
CPHD and IGHD cases can be explained by genetic 
defects in coding regions of the genes associated with 
pituitary hormone deficiencies. This is surprising, because 
the CPHD and IGHD patients in the Dutch cohort have the 
same phenotype as patients from other countries, where 
mutations in PROP1, POU1F1 and HESX1 are much more 
prevalent.
Although the chance of finding a mutation in PROP1, 
POU1F1 and HESX1 in a CPHD patient is very low for 
Western European countries, especially the Netherlands, 
most clinicians still routinely send DNA of their CPHD 
patients for genetic screening of PROP1, POU1F1 and 
HESX1. However, based on the above mentioned find-
ings, we can conclude that defects in PROP1, POU1F1 and 
HESX1 are usually not the cause of CPHD in Dutch sporadic 
CPHD patients. It would therefore make sense to recom-
mend against screening of PROP1, POU1F1 and HESX1 as 
part of routine work-up for Dutch sporadic CPHD patients. 
However, in order to justify such a recommendation, defects 
in the regulatory regions of these genes should first be ruled 
out.
The regulatory regions of PROP1, POU1F1 and HESX1 
are largely located outside the coding regions and are thus 
not covered by Whole Exome Sequencing. Therefore, in the 
current study, we manually sequenced regulatory regions 
of PROP1, POU1F1 and HESX1 among 88 patients with 
CPHD. Since patients with HESX1 mutations can initially 
present with IGHD only, we also screened 92 patients with 
IGHD. We compared genotype frequencies in our CPHD 
cohort with those found in healthy controls from the 1000 
genomes database and we studied promoter SNPs in relation 
to phenotypic data.
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Patients and methods
Patients
Clinical data of the patients were collected from the Dutch 
National Registry of Growth Hormone Treatment, where 
clinical and laboratory parameters of GH-treated Dutch 
patients are being registered. We included all GH-treated 
children and adults registered in the Dutch National Registry 
of Growth Hormone Treatment between 1992 and 2003, who 
had deficiencies of GH and one or more additional hormonal 
axes and were treated in the hospitals participating in the 
Fig. 1  Prevalence of PROP1, 
POU1F1 and HESX1 mutations 
in CPHD patients as reported 
in the literature, according to 
country of origin (see “Meth-
ods” section for literature 
search criteria). Apart from the 
Moroccan data, most popula-
tions included both familial 
and sporadic CPHD cases. For 
original data, see Ref [8–20]. 
? = no mutation rate available. 
*The exact mutation frequency 
in French and German sporadic 
CPHD patients could not be 
deduced from the literature [13, 
21]
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study. Patients with Growth Hormone deficiency (GHD) of 
known cause, such as a brain tumour, brain surgery, brain 
irradiation and known syndromes, were excluded. GHD was 
defined as a peak GH response below 6.7 μg/L (20 mU/L) 
to arginine or clonidine test, or 10 μg/L (< 30 mU/L) com-
bined with serum IGF-I < − 2 SDS. Patients were classified 
as having severe IGHD or partial IGHD (pIGHD) based on 
a scoring system including height SDS (HSDS), maximum 
stimulated GH levels, IGF-I SDS and IGFBP-3 SDS. Central 
hypothyroidism was defined as abnormal TRH test or TSH 
levels that were low or inadequate for low (F) T4, using ref-
erence ranges of each participating hospital. Central hypo-
cortisolism was defined as abnormal CRF/ACTH/glucagon 
test or ACTH levels which were low or inadequate for low 
cortisol. Central hypogonadism was diagnosed when LH, 
FSH and estrogen/testosterone or LHRH test were low for 
age, or when spontaneous puberty had not occurred at age 14 
years. Prolactin deficiency was defined as abnormal random 
prolactin or during TRH testing. For all hormone values, 
reference values of the participating hospitals are available 
upon request.
The Medical Ethics Committees of all participating hos-
pitals approved the study. Informed consent was obtained 
from all participating patients and their parents, if patients 
were younger than 18 years.
Methods
PCR Genomic DNA was extracted from samples of periph-
eral venous blood according to standard procedures. For 
PCR, we used the following Qiagen reagents: 10× PCR 
buffer, 0.2  mM dNTP mixture and 5 units/μL Taq DNA 
Polymerase. After gel electrophoresis, we purified the PCR 
products using the High Pure PCR product Purification kit 
 (QIAGEN®, Hilgen, Germany) or the Illustra GFX 96 PCR 
Purification Kit (GE  Healthcare®, Leiderdorp, the Nether-
lands) according to the supplied protocols. PCR conditions 
and amplification programs are available upon request. We 
studied the regulatory regions of POU1F1 as described by 
Delhase et al. [28] and the promoter of HESX1 as described 
by Eroshkin et al. [29]. Primer sequences were designed using 
the Primer3 program. Nucleotide sequences were obtained 
from Ensembl (PROP1: ENSG00000175325; POU1F1 
ENSG00000064835; HESX1 ENSG00000163666). Primer 
sequences for CEA and CEB of PROP1 were kindly pro-
vided by Godi et al. [7] and Ward et al. [30]. An overview 
of the regulatory regions of PROP1, POU1F1 and HESX1 is 
shown in Fig. 2. The primers were ordered from Integrated 
DNA Technologies Inc (Iowa, United States), dissolved in 
sterile  H2O to a concentration of 50 pmol/μL and stored at 
− 20 °C until further use. From this stock, aliquots with a 
working concentration of 25 pmol/μL were made and stored 
at − 20 °C.
Sequencing Sequencing  was outsourced to Baseclear, a 
commercial DNA sequencing company in Leiden, the Neth-
erlands, and carried out using an ABI3730XL sequencer. 
The results were analyzed for mutations using Sequencher4.1 
(Genecodes, Michigan, United States).
Statistics We analysed clinical and genotypic data by means 
of ANOVA and Chi square tests using SPSS version 22.0.
Literature In order to make an overview of PROP1 mutation 
frequencies according to country of origin, we performed a 
pubmed search using ‘PROP1 AND mutation AND com-
bined pituitary hormone deficiency’ (filter: English). We 
only selected articles of which the full text manuscript was 
Fig. 2  Overview of regulatory 
regions of PROP1, POU1F1 
and HESX1. CEA conserved 
element A, CEB conserved 
element B
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available online or sent to us by the authors upon request. 
Articles in which the country of origin of the patients was 
mixed or unclear, were excluded.
In silico analysis of  new variant We used online software 
PROMO 3.0 [31] to predict changes in transcription factor 
binding sites in the POU1F1 promoter region.
Results
We included 88 CPHD patients (63 M/25 F) and 92 patients 
(64 M/28 F) with IGHD, either classified as severe (‘IGHD’) 
or partial IGHD (‘pIGHD’). The male predominance in our 
cohort is in accordance with the male predominance in the 
overall Dutch CPHD and IGHD population.
Clinical characteristics of the CPHD and IGHD patients 
are shown in Table 1. All CPHD patients had at least GHD 
and thyroid hormone replacement, while 79% of the patients 
additionally required glucocorticoid hormone replacement 
and 85% required induction of puberty. Hypoprolactinae-
mia was present in only 15% of CPHD patients tested and 
four patients (5%) had diabetes insipidus. Neonatal jaundice, 
neonatal hypoglycaemia and micropenis, suggestive of early 
pituitary hormone deficiencies, were present in 62, 43 and 
38% (of boys), respectively. 79 patients underwent MRI, 
82% of them had an abnormal pituitary on MRI (Figure S1). 
Clinical characteristics of the (p)IGHD patients screened for 
defects in the HESX1 promoter are also shown in Table 1.
We identified nine genetic variants in the CPHD cohort; 
six in the regulatory regions of PROP1 and three in the regu-
latory regions of POU1F1 (Table 2). We did not find any 
variants in the HESX1 promoter in either the (p)IGHD or 
CPHD patients. Four of the PROP1 promoter SNPs have 
been previously reported by Godi et al. [7]. The genotype 
frequencies did not differ significantly from the frequencies 
found in healthy controls from the 1000 Genome Project 
(Table 2).
A polymorphism in PROP1, consisting of a 3 bp (TAG) 
deletion in the promoter (ins/delTAG, rs148607624), which 
was previously shown to be more frequent among CPHD 
patients than among controls [7], was associated with a 
slightly more severe phenotype (i.e. shorter height, lower 
peak GH during GH test, and lower serum IGF-I SD scores) 
in the current cohort (Table 3). The other SNPs were not 
related to phenotype.
One of the POU1F1 variants had not been reported in 
the 1000 Genomes database by January 2017. We found this 
new heterozygous variant, − 1295C > T in a girl born Small 
for Gestational Age (SGA) (2500 g and 45 cm after 41 w of 
gestation). At 6 months of age, her length was − 4.3 SDS. 
After endocrine function tests, she was diagnosed with GH 
deficiency and later with central hypothyroidism. She also 
required hydrocortisone treatment and sex steroid treatment 
Table 1  Clinical characteristics of the CPHD and (p)IGHD patients 
in this study
Data are expressed as mean (SD) or %
SDS standard deviation score
a No cases of central hypothyroidism, only primary hypothyroidism or 
borderline low FT4 values during GH therapy
CPHD (p)IGHD
Sex 63 M/25 F 64 M/28 F
Birth weight (kg)
(SDS)
3.0 (0.8)
− 0.6 (1.4)
3.1 (0.6)
− 0.7 (1.3)
Birth length (kg)
(SDS)
49.4 (3.0)
− 0.3 (1.4)
48.1 (3.6)
− 0.7 (1.3)
Gestational age (w) 38.9 (2.8) 38.9 (2.6)
Neonatal jaundice 62% 21%
Neonatal hypoglycaemia 43% 10%
Micropenis (% of boys) 38% 17%
Age at start of GH treatment (y) 4.0 (3.5) 6.4 (3.4)
Height SDS at start of GH − 3.0 (1.3) − 3.2 (0.9)
GH peak during Arginine test (μg/L) 1.7 (2.0) 3.1 (2.0)
GH peak during Clonidine test (μg/L) 1.5 (1.3) 3.7 (2.0)
IGF-I SDS − 4.4 (3.0) − 3.3 (2.4)
Thyroid hormone replacement 100% 14%a
Hydrocortison treatment 79% 0
Induction of puberty 85% 0
Hypoprolactinemia 15% 0
Diabetes insipidus 5% 0
Affected first-degree relatives 5% 7%
Table 2  New and known variants in the regulatory regions of 
PROP1, POU1F1 and HESX1 in the current study, compared to Brit-
ish control data from the 1000 genomes database
NS not significant
Gene rs number Frequency (%) in 
current study/British 
controls* (p)
POU1F1 promoter New variant 
(− 1295C > T)
1.1/– (NS)
POU1F1 promoter rs10511134 (T > A) 43.8/50.5 (NS)
POU1F1 promoter rs300982 (C > T) 10.9/3.8 (NS)
POU1F1 DRR No variants found –
PROP1 CEA rs12654239 (G > T) 61.4/53.3 (NS)
PROP1 CEB rs4431364 (C > G) 28.9/31.9 (NS)
PROP1 CEB rs4498267 (C > T) 12.5/13.2 (NS)
PROP1 CEB rs148607624 (ins/
delTAG)
1.7/0.5 (NS)
PROP1 CEB rs141213827 (delG) 1.1/0 (NS)
PROP1 CEB rs113776172 (C > A) 1.1/0 (NS)
HESX1 promoter No variants found –
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due to lack of pubertal development. Her MRI revealed no 
visible abnormalities.
To predict the possible impact of this new POU1F1 pro-
moter variant, we performed in silico analysis using online 
software. The binding sites for several transcription factors 
disappear when the C located 1295 bp upstream of the tran-
scription start site is replaced by a T. In addition, the new 
variant creates new binding sites for other transcription fac-
tors, shown in Supplementary table S1, which means that 
transcription of POU1F1 might be affected by this variant.
Discussion
We studied the regulatory regions of the pituitary transcrip-
tion factors PROP1, POU1F1 and HESX1 in a cohort of 88 
CPHD patients, in order to find an explanation for their phe-
notype. Since patients with HESX1 mutations can initially 
present with IGHD only, we also screened 92 patients with 
severe or partial IGHD (64 M/28 F).
In the CPHD patients, we identified eight known poly-
morphisms (six in the regulatory regions of PROP1 and two 
in the regulatory regions of POU1F1) and one new POU1F1 
variant. No variants in the HESX1 promoter were identified 
in the 88 CPHD and 92 (p)IGHD patients.
Since CPHD can be caused by both heterozygous and 
homozygous POU1F1 mutations, the new heterozygous 
POU1F1 promoter variant − 1295 C > T could be the cause 
of CPHD in this patient. We performed in silico analysis to 
predict its possible impact, which showed that the − 1295 
C > T variant might create new binding sites for several tran-
scription factors in the POU1F1 promoter region. In theory, 
this could increase or decrease the activity of the promoter, 
and therefore alter the expression of POU1F1. However, 
even though this new variant might explain the phenotype of 
this individual patient, the general conclusion of this study 
is that variants in regulatory regions of PROP1, POU1F1 
and HESX1 are rare in patients with sporadic CPHD in the 
Netherlands.
These results are very important for clinicians and 
researchers in the field of congenital hypopituitarism. Most 
clinicians routinely send DNA of their familial and sporadic 
CPHD patients to genetic laboratories for genetic screening 
of PROP1, POU1F1 and HESX1. However, the chance of 
finding a mutation in these genes in a CPHD patient depends 
strongly on the country of origin and is very low for Western 
European countries, especially for the Netherlands. Our pre-
vious study already showed that the vast majority of Dutch 
sporadic CPHD cases could not be explained by defects in 
the coding regions of PROP1, POU1F1 and HESX1 [24]. 
The results of the current study show that defects in their 
regulatory regions do not explain the phenotype either.
Based on the current study and our previous studies 
investigating pituitary transcription factors, we therefore 
recommend that genetic screening of PROP1, POU1F1 and 
HESX1 should no longer be part of routine work-up for spo-
radic CPHD patients in the Netherlands.
The fact that we studied a Dutch cohort, suggests 
that our results only justify recommendations for Dutch 
patients. However, similar recommendations might also 
apply to other Western European countries, because of our 
shared genetic background. The genetic composition of 
European countries is in part determined by human migra-
tion in the Paleolithic and Neolithic periods, but also by 
more recent migration in the fifteenth and seventeenth 
century. The genetic background seems to be comparable 
for most Western European countries, except for the Ibe-
rian Peninsula. This has been confirmed by recent research 
concerning PROP1 mutation frequencies in different coun-
tries [32, 33]. PROP1 mutation rates are highest in Rus-
sian, Eastern European, Portuguese and Brazilian cohorts. 
In Western and Southern European Countries, PROP1 
frequencies among sporadic CPHD patients are generally 
low (United Kingdom 0%, Spain 5.6%, Portugal 6.9%, 
Table 3  Severity of GHD 
phenotype according to PROP1 
SNP rs148607624 (ins/delTAG)
a Numbers do not add up to 88, because height SDS at start GH was not available for two patients. In these 
two patients, GH was started based on deficiencies of all other pituitary axes, low IGF-I SDS and two 
severely deficient GH tests
N Mean SD Min Max p
Height at start of GH treatment
 TAG/TAG 84 − 3.1 1.3 − 6.0 0.0 0.22
 –/TAG 2a − 4.2 0.4 − 4.5 − 4.0
Mean of peak GH values during clonidine and arginine tests (μg/L)
 TAG/TAG 53 1.8 2.1 0.0 9.4 0.49
 –/TAG 3 0.9 0.9 0.0 1.7
IGF-I SDS at start of GH treatment
 TAG/TAG 57 − 3.8 2.5 − 9.4 1.4 0.010
 –/TAG 3 − 7.8 2.1 − 9.0 − 5.3
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Italy 2.9%, Fig. 1b). De Rienzo et al. [33] state that after 
excluding Russian, Eastern European, Portuguese and Bra-
zilian cohorts, the global frequency of PROP1 mutation 
decreases from 11.2 to 5.1% (a decrease from 6·7 to 1·9% 
in sporadic patients and 48.5–35.8% in familial cases). The 
mutation prevalence found in the current Dutch cohort is 
among the lowest in Europe.
In the case of sporadic CPHD, mutations are only likely 
to be identified in patients from countries with a high preva-
lence of mutations and patients who present with a pheno-
type that strongly favours the analysis of a particular gene, 
such as LHX3 (hypopituitarism, sensorineural hearing loss 
and skeletal abnormalities) or HESX1 (hypopituitarism and 
SOD) [33]. Parents of sporadic CPHD patients without these 
specific phenotypes should be informed about these low 
mutation rates in order to prevent false expectations.
In contrast to sporadic cases, familial subjects from all 
countries should undergo genetic analysis if possible. In 
these familial cases, the likelihood of detecting a mutation 
within any of the transcription factor genes is much higher 
[10–16, 19, 20, 33].
In conclusion, mutations in the regulatory regions 
of pituitary transcription factors PROP1, POU1F1 and 
HESX1 are rare in Western Europe, especially in the Neth-
erlands. Based on this and previous studies of our group, 
and based on mutation frequencies from other countries, 
we conclude that these mutations do not significantly con-
tribute to the prevalence of IGHD or CPHD. We therefore 
recommend against routine genetic screening of PROP1, 
POU1F1 and HESX1 among sporadic CPHD patients in 
Western Europe, especially in the Netherlands. Further 
research should focus on the identification of new candi-
date genes, using a whole genome/exome approach.
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